Eton Pharmaceuticals, Inc. Operating Income Loss

• Eton Pharmaceuticals, Inc. showed an increase of +67.5% in Operating Income Loss from 2024 to 2025.
• This data is from Eton Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on March 19, 2026.
• XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
• Over the full 8 years of available data (2018 to 2025), Eton Pharmaceuticals, Inc.'s Operating Income Loss has grown by 91.8%.
• Historical annual values: Fiscal year 2025: -$844.0 thousand | Fiscal year 2024: -$2.60 million | Fiscal year 2023: -$1.19 million | Fiscal year 2022: -$8.26 million | Fiscal year 2021: -$1.50 million | Fiscal year 2020: -$27.11 million | Fiscal year 2019: -$18.60 million | Fiscal year 2018: -$10.32 million.
• Data sourced from SEC EDGAR public filings as of June 20, 2026.

Last verified: June 20, 2026